Quantitative analysis of 18F-(E)-N-(3-iodoprop-2-enyl)-2β-carbofluoroethoxy-3β-(4′-methyl-phenyl) nortropane binding to the dopamine transporter in Parkinson …

P Fazio, P Svenningsson, A Forsberg… - Journal of Nuclear …, 2015 - Soc Nuclear Med
18F-(E)-N-(3-iodoprop-2-enyl)-2β-carbofluoroethoxy-3β-(4′-methyl-phenyl) nortropane
(18F-FE-PE2I) is a recently developed radioligand for the in vivo quantification of the …

Optimal acquisition time window and simplified quantification of dopamine transporter availability using 18F-FE-PE2I in healthy controls and Parkinson disease …

I Sonni, P Fazio, M Schain, C Halldin… - Journal of Nuclear …, 2016 - Soc Nuclear Med
18F-(E)-N-(3-iodoprop-2-enyl)-2β-carbofluoroethoxy-3β-(4′ methylphenyl) nortropane (18F-
FE-PE2I) is a newly developed dopamine transporter (DAT) PET radioligand. Full …

Whole-body biodistribution and dosimetry of the dopamine transporter radioligand 18F-FE-PE2I in human subjects

H Lizana, L Johansson, J Axelsson… - Journal of Nuclear …, 2018 - Soc Nuclear Med
18F-(E)-N-(3-iodoprop-2-enyl)-2β-carbofluoroethoxy-3β-(4′-methyl-phenyl) nortropane
(18F-FE-PE2I) was recently developed and has shown adequate affinity and high selectivity …

Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT

MR Davis, JR Votaw, JD Bremner… - Journal of Nuclear …, 2003 - Soc Nuclear Med
The aim of this study was to do an initial assessment of the usefulness of 2β-carbomethoxy-
3β-(4-chlorophenyl)-8-(2-18F-fluoroethyl) nortropane (18F-FECNT) PET scanning in …

Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I

T Sasaki, H Ito, Y Kimura, R Arakawa… - Journal of Nuclear …, 2012 - Soc Nuclear Med
18F-(E)-N-(3-iodoprop-2 E-enyl)-2β-carbofluoroethoxy-3β-(4-methylphenyl) nortropane (18F-
FE-PE2I) is a new PET radioligand with a high affinity and selectivity for the dopamine …

Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders

L Appel, M Jonasson, T Danfors… - Journal of Nuclear …, 2015 - Soc Nuclear Med
In idiopathic Parkinson disease and atypical parkinsonian disorders, central dopaminergic
and overall brain functional activity are altered to different degrees, causing difficulties in …

In vivo PET quantification of the dopamine transporter in rat brain with [18F] LBT-999

S Sérrière, C Tauber, J Vercouillie, D Guilloteau… - Nuclear Medicine and …, 2014 - Elsevier
Introduction We examined whether [18 F] LBT-999 ((E)-N-(4-fluorobut-2-enyl) 2β-
carbomethoxy-3β-(4'-tolyl) nortropane) is an efficient positron emission tomography (PET) …

Quantification of dopamine transporter density with [18F] FECNT PET in healthy humans

JA Nye, JR Votaw, JD Bremner, MR Davis… - Nuclear medicine and …, 2014 - Elsevier
Abstract Introduction Fluorine-18 labeled 2β-carbomethoxy-3β-(4-chlorophenyl)-8-(2-
fluoroethyl) nortropane ([18 F] FECNT) binds reversibly to the dopamine transporter (DAT) …

Kinetic analysis and quantification of the dopamine transporter in the nonhuman primate brain with 11C-PE2I and 18F-FE-PE2I

A Varrone, M Tóth, C Steiger, A Takano… - Journal of Nuclear …, 2011 - Soc Nuclear Med
18F-(E)-N-(3-iodoprop-2-enyl)-2β-carbofluoroethoxy-3β-(4′-methyl-phenyl) nortropane
(18F-FE-PE2I) is a novel radioligand for dopamine transporter (DAT) PET. As compared with …

Synthesis and Biological Evaluation of [18F]FECNT-d4 as a Novel PET Agent for Dopamine Transporter Imaging

S Cao, J Tang, C Liu, Y Fang, L Ji, Y Xu… - Molecular Imaging and …, 2021 - Springer
Purpose The dopamine transporter (DAT) is a marker of the occurrence and development of
Parkinson's disease (PD) and other diseases with nigrostriatal degeneration. 2β …